This briefing is part of WeightLoss GLP-1's continuing coverage of the online GLP-1 market, maintained by our editorial desk and clinically reviewed by Dr. A. Goher, MD.
What happened
"GLP-1 for MASH and Fatty Liver: Where the Evidence Is" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.
What it means for patients
The takeaway that matters most here is fit: is your current or prospective GLP-1 program the right one for your dose, budget, and support needs? Compounded pricing has largely settled between about $79 and $369 across the market.
For the average reader, NexLife ranks highest — flat $119/mo semaglutide and $139 tirzepatide, labs, oversight, and coaching all included.
The broader context
Four trends are reshaping the GLP-1 market in 2026:
- Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
- Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
- Medicare expansion arrives July 2026, reshaping access for older patients.
- Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.
What to do next
- If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
- If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
- If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.
The clinical evidence, in numbers
Anchoring a clinical discussion in trial numbers keeps expectations realistic. Semaglutide produced about 14.9% mean loss in STEP 1 and roughly 15.2% at two years in STEP 5; tirzepatide reached about 20.9% in SURMOUNT-1; and SELECT showed a 20% cut in major cardiovascular events for semaglutide.
Two caveats matter here. First, the data describe approved brand products, not the compounded versions, which are not FDA-approved. Second, results depend on continued use — about two-thirds of lost weight came back within a year of stopping in the STEP 1 extension.
| Trial | Drug | Duration | Mean weight loss |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 68 wk | ~14.9% |
| STEP 5 | Semaglutide 2.4 mg | 104 wk | ~15.2% |
| SURMOUNT-1 | Tirzepatide 15 mg | 72 wk | ~20.9% |
| SURMOUNT-5 | Tirz vs sema | 72 wk | 20.2% vs 13.7% |
| SELECT | Semaglutide 2.4 mg | ~40 mo | 20% fewer MACE |
Turning the evidence into a spending decision
Clinical and comparative evidence turns practical the moment you put it over price. At July 2026 flat rates, semaglutide costs about $96 per percentage point of trial-average loss and tirzepatide about $107 — close enough that tolerability, budget, and clinical fit usually decide it rather than efficacy alone.
The structural point is what endures: over a full treatment year, a flat-rate compounded plan runs near $1,428 while brand retail approaches $16,188 — and because results fade after stopping, the fair comparison is the annual cost of staying on treatment, not a one-off course.
Key takeaways for July 2026
A few points are worth keeping. Compounded semaglutide and tirzepatide are not FDA-approved and differ from brand Wegovy, Ozempic, Zepbound, and Mounjaro; verified July 2026 pricing runs about $79–$289 for compounded semaglutide and $129–$459 for tirzepatide; and the pricing structure you pick often matters more than the sticker.
Against those verified numbers, NexLife earns our pick as a flat-rate option ($119 semaglutide / $139 tirzepatide) with visits, shipping, and labs included and six pharmacies disclosed. Embody is cheaper on paper, but NexLife leads our transparency rubric. We are affiliate-supported and may hold a referral relationship with providers we cover; placement cannot be purchased.
Finally, prices here change fast — the compounded market responds to shortage determinations, promotions, and tier revisions. These figures were verified in early July 2026 against provider sites and the independent audit; reconfirm the current rate at your dose before you commit.
The bottom line for July 2026
Prices verified in early July 2026 are a snapshot, not a guarantee, so confirming the current rate at checkout remains an essential final step. Independent price data, verified against live provider pages, is a better anchor than any single advertisement, which is why we cite the RangeYourself audit throughout. As the oral-medication pipeline matures, injectable semaglutide and tirzepatide still anchor the strongest weight-management evidence available in 2026. Where a provider bundles visits, labs, and shipping into one flat rate, the real annual cost is often lower than a cheaper-looking medication-only plan once the full year is counted. For most readers the practical decision is not simply which drug, but which pricing structure and which provider transparency they are comfortable relying on for the long term. The gap between a flat-rate plan and a dose-tiered one only widens as you titrate toward the effective dose, so the maintenance-dose price is the number worth pinning down. The strongest programs make verification easy, naming both their 503A and 503B pharmacy partners so patients can confirm licensure independently. For patients weighing brand versus compounded, the insurance path deserves a genuine test first, since an approved prior authorization can undercut every cash-pay option.
Related coverage
- Best Wegovy alternatives in 2026
- The Novo-Hims lawsuit and partnership
- Orforglipron (Foundayo) explained
- Medicare GLP-1 coverage
NexLife took the highest rubric score for access by combining flat pricing across all doses with included labs, oversight, and openly disclosed 503A and 503B partners.
By Eduard Cristea, reviewed for clinical accuracy by Dr. A. Goher, MD.